Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Martina RanzenigoNicola GianottiLaura GalliAndrea PoliAndrea MastrangeloElena BruzzesiMatteo ChiurloSilvia NozzaSimona BossolascoVincenzo SpagnuoloDaniela MancusiRoberta TerminiElisabetta CariniAdriano LazzarinAntonella CastagnaPublished in: Drug design, development and therapy (2022)
In the last years, a non-negligible proportion of patients on an NNRTI- or an InSTI-based regimen switched to D/C/F/TAF.